Potential future therapies for psoriasis

Seminars in Cutaneous Medicine and Surgery

Volumn 24, Issue 1, 2005, Pages 58-63

  Papp, K Alexander ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BEVACIZUMAB; CHEMOKINE RECEPTOR ANTAGONIST; CNTO 1275; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; EFALIZUMAB; ETANERCEPT; FUMARIC ACID DERIVATIVE; FUMERIC ACID; GALIXIMAB; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; ISA 247; LENERCEPT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; ONERCEPT; PIMECROLIMUS; ROSIGLITAZONE; TAZAROTENE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE EXACERBATION; ERYTHEMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NEPHROTOXICITY; PSORIASIS; REVIEW; SEPSIS; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CYCLOSPORINE; DERMATOLOGIC AGENTS; FORECASTING; FUMARATES; HUMANS; NICOTINIC ACIDS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TACROLIMUS; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 15744364872     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2005.01.005     Document Type: Review

References (82)

1. J.G. Krueger The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1 23 quiz 23-6
2. D.B. Dubin, W. Tanner, R. Ellis Biologics for psoriasis Nat Rev Drug Discov 2 2003 855 856
3. W. Sterry Biological therapies in the systemic management of psoriasis International Consensus Conference Br J Dermatol 151 suppl 69 2004 3 17
4. G.G. Krueger A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 2002 821 833
5. K. Papp The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody J Am Acad Dermatol 45 2001 665 674
6. K.A. Papp Etanercept in psoriasis Expert Opin Pharmacother 5 2004 2139 2146
7. E.C. Keystone Appropriate and effective rheumatoid arthritis control Role of TNF antagonists Drugs Today (Barc) 39 suppl B 2003 9 15
8. W.J. Sandborn Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease Curr Gastroenterol Rep 5 2003 501 505
9. D.I. Spencer A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics Proteomics 2 2002 271 279
10. T. Maeda Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody Int J Hematol 74 2001 70 75
11. G. Van Assche, P. Rutgeerts Anti-TNF agents in Crohn's disease Expert Opin Investig Drugs 9 2000 103 111
12. W.J. Sandborn, S.B. Hanauer Antitumor necrosis factor therapy for inflammatory bowel disease A review of agents, pharmacology, clinical results, and safety Inflamm Bowel Dis 5 1999 119 133
13. R. Sanmarti [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab] Med Clin (Barc) 122 2004 321 324
14. G. Krueger, K. Callis Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis Arch Dermatol 140 2004 218 225
15. I.K. Nahar Infliximab treatment of rheumatoid arthritis and Crohn's disease Ann Pharmacother 37 2003 1256 1265
16. N. Scheinfeld Adalimumab (HUMIRA) A review J Drugs Dermatol 2 2003 375 377
17. H.M. Algood, J. Chan, J.L. Flynn Chemokines and tuberculosis Cytokine Growth Factor Rev 14 2003 467 477
18. D.R. Roach TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection J Immunol 168 2002 4620 4627
19. P. Rutgeerts, G. Van Assche, S. Vermeire Optimizing anti-TNF treatment in inflammatory bowel disease Gastroenterology 126 2004 1593 1610
20. E. VandenBerg The role of the cytoskeleton in cellular adhesion molecule expression in tumor necrosis factor-stimulated endothelial cells J Cell Biochem 91 2004 926 937
21. B. Settles Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide Cell Mol Biol (Noisy-le-grand) 47 2001 1105 1114
22. J.L. Dunne Control of leukocyte rolling velocity in TNF-alpha-induced inflammation by LFA-1 and Mac-1 Blood 99 2002 336 341
23. J.J. Gomez-Reino Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk A multicenter active-surveillance report Arthritis Rheum 48 2003 2122 2127
24. P. Rutgeerts A critical assessment of new therapies in inflammatory bowel disease J Gastroenterol Hepatol 17 suppl 2002 S176 S185
25. H. Wiendl, R. Hohlfeld Therapeutic approaches in multiple sclerosis lessons from failed and interrupted treatment trials BioDrugs 16 2002 183 200
26. The Lenercept Multiple Sclerosis Study Group The University of British Columbia MS/MRI Analysis Group TNF neutralization in MS results of a randomized, placebo-controlled multicenter study Neurology 53 1999 457 465
27. K.B. Gordon Adalimumab in patients with moderate to severe chronic plaque psoriasis, in EULAR, Annual Scientific Meeting 2004 Berlin, Germany
28. A.B. Gottlieb Infliximab induction therapy for patients with severe plaque-type psoriasis a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
29. U. Chaudhari Efficacy and safety of infliximab monotherapy for plaque-type psoriasis A randomised trial Lancet 357 2001 1842 1847
30. S.N. Nikas, A.A. Drosos Onercept Serono Curr Opin Investig Drugs 4 2003 1369 1376
31. I. Trinchard-Lugan Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers Eur Cytokine Netw 12 2001 391 398
32. G. Hasko, C. Szabo IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases Regulation of T helper 1/T helper 2 responses Br J Pharmacol 127 1999 1295 1304
33. C.L. Kauffman A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis J Invest Dermatol 123 2004 1037 1044
34. A.B. Gottlieb Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis Clin Immunol 111 2004 28 37
35. C.L. Leonardi Efalizumab An overview J Am Acad Dermatol 49 suppl 2003 S98 S104
36. J.C. Yang A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
37. H. Wu Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb Proc Natl Acad Sci USA 95 1998 6037 6042
38. B.J. Nickoloff, F.O. Nestle Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities J Clin Invest 113 2004 1664 1675
39. C. Gorman, M. Leandro, D. Isenberg B cell depletion in autoimmune disease Arthritis Res Ther 4 suppl 5 2003 S17 S21
40. E.C. Keystone Safety issues related to emerging therapies for rheumatoid arthritis Clin Exp Rheumatol 22 suppl 2004 S148 S150
41. C.E. Griffiths Ciclosporin in psoriasis clinical practice An international consensus statement Br J Dermatol 150 suppl 67 2004 11 23
42. F.J. Dumont ISAtx-247 (Isotechnika/Roche) Curr Opin Invest Drugs 5 2004 542 550
43. Bissonnette R, et al. FC06.9: A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis, in EADV 13th Congress, Nov 2004 Florence. 2004: Florence, Italy
44. Wolff, K,, et al. Current concepts and review of pimecrolimus in the treatment of psoriasis. Dermatol Clin 22461-465, ix-x, 2004
45. A. Stuetz, M. Grassberger, J.G. Meingassner Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity Semin Cutan Med Surg 20 2001 233 241
46. K. Rappersberger Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated J Invest Dermatol 119 2002 876 887
47. J.J. Hoefnagel Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis Br J Dermatol 149 2003 363 369
48. N.H. Litjens Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses Eur J Immunol 34 2004 565 575
49. F. Treumer Dimethylfumarate is a potent inducer of apoptosis in human T cells J Invest Dermatol 121 2003 1383 1388
50. R. Loewe Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells J Immunol 168 2002 4781 4787
51. N.L. Magis The treatment of psoriasis with etretinate and acitretin a follow up of actual use Eur J Dermatol 10 2002 517 521
52. D.L. Crowe, R.A. Chandraratna A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands Breast Cancer Res 6 2004 R546 R555
53. J.V. Smit Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin J Am Acad Dermatol 51 2004 257 264
54. I.S. Kim Differential effects of 9-cis retinoic acid on expression of CC chemokine receptors in human monocytes Biochem Pharmacol 68 2004 611 620
55. P. Costet Retinoic acid receptor-mediated induction of ABCA1 in macrophages Mol Cell Biol 23 2003 7756 7766
56. M. Iwata, Y. Eshima, H. Kagechika Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors Int Immunol 15 2003 1017 1025
57. J. Marill Retinoic acid metabolism and mechanism of action A review Curr Drug Metab 4 2003 1 10
58. S.Y. Na Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB J Biol Chem 274 1999 7674 7680
59. P.S. Yamauchi, D. Rizk, N.J. Lowe Retinoid therapy for psoriasis Dermatol Clin 22 2004 467 476
60. D.D. Tang-Liu, R.M. Matsumoto, J.I. Usansky Clinical pharmacokinetics and drug metabolism of tazarotene A novel topical treatment for acne and psoriasis Clin Pharmacokinet 37 1999 273 287
61. S. Cuzzocrea Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation Eur J Pharmacol 483 2004 79 93
62. S.G. Miller Discovery of cytokine mimics using cell-based systems Drug Discov Today 5 12 suppl 1 2000 77 83
63. A. Whitty, C.W. Borysenko Small molecule cytokine mimetics Chem Biol 6 1999 R107 R118
64. L.C. Borish, J.W. Steinke 2. Cytokines and chemokines J Allergy Clin Immunol 111 suppl 2003 S460 S475
65. P.M. Murphy International union of pharmacology. XXII. Nomenclature for chemokine receptors Pharmacol Rev 52 2000 145 176
66. F.W. Luscinskas C-C and C-X-C chemokines trigger firm adhesion of monocytes to vascular endothelium under flow conditions Ann N Y Acad Sci 902 2000 288 293
67. P.L. Podolin, J.F. Callahan, B.J. Bolognese Attenuation of murine collagen-induced arthritis by a novel, potent and selective small molecule inhibitor of I{kappa}B kinase 2, TPCA-1, occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation J Pharmacol Exp Ther 312 2005 373 381
68. M.R. Arkin Binding of small molecules to an adaptive protein-protein interface Proc Natl Acad Sci USA 100 2003 1603 1608
69. M. Hayashi Biological activity of a novel nonpeptide antagonist to the interleukin-6 receptor 20S,21-epoxy-resibufogenin-3-formate J Pharmacol Exp Ther 303 2002 104 109
70. T.R. Gadek, R.S. McDowell Discovery of small molecule leads in a biotechnology datastream Drug Discov Today 8 2003 545 550
71. T.R. Gadek, J.B. Nicholas Small molecule antagonists of proteins Biochem Pharmacol 65 2003 1 8
72. T.R. Gadek Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule Science 295 2002 1086 1089
73. T.A. Kelly Cutting edge A small molecule antagonist of LFA-1-mediated cell adhesion J Immunol 163 1999 5173 5177
74. K.J. Smith, H. Skelton Molluscum contagiosum recent advances in pathogenic mechanisms, and new therapies Am J Clin Dermatol 3 2002 535 545
75. H.R. Luttichau The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor Eur J Immunol 31 2001 1217 1220
76. T.A. Ramelot Myxoma virus immunomodulatory protein M156R is a structural mimic of eukaryotic translation initiation factor eIF2alpha J Mol Biol 322 2002 943 954
77. A. Alcami, G.L. Smith Soluble interferon-gamma receptors encoded by poxviruses Comp Immunol Microbiol Infect Dis 19 1996 305 317
78. K. Mossman Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins Virology 208 1995 762 769
79. J.F. Ohren Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat Struct Mol Biol 11 2004 1192 1197
80. J. Saklatvala The p38 MAP kinase pathway as a therapeutic target in inflammatory disease Curr Opin Pharmacol 4 2004 372 377
81. P.P. Roux, J. Blenis ERK and p38 MAPK-activated protein kinases A family of protein kinases with diverse biological functions Microbiol Mol Biol Rev 68 2004 320 344
82. D.S. Brown A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis Bioorg Med Chem Lett 14 2004 5383 5387